IDH2 and glioblastoma: Six years after this, the patient remained in remission with no GBM recurrence despite carrying wild-type copies for the IDH1 and IDH2 genes together with mutations in oncogenes such as PIK3CA, clinically associated with patients who develop GBM at a young age and who had a poor survival prognosis [73].